• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Genentech

Genentech

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Publicis Groupe: Third Quarter 2017 Revenue

    Publicis Groupe: Third Quarter 2017 Revenue

  2. FDA Grants Priority Review for Genentech ’s Perjeta (Pertuzumab) for Adjuvant Treatment of HER2-Positive Early Breast Cancer

    FDA Grants Priority Review for Genentech ’s Perjeta (Pertuzumab) for Adjuvant Treatment of HER2-Positive Early Breast Cancer

  3. PPD Strengthens Regulatory Consulting and Ophthalmology Expertise

    PPD Strengthens Regulatory Consulting and Ophthalmology Expertise

  4. Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma

    Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma

12345

©2017 Morningstar Advisor. All right reserved.